Journal
NPJ PRECISION ONCOLOGY
Volume 1, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41698-017-0005-2
Keywords
-
Categories
Funding
- Ludwig Institute for Cancer Research
- NIH grant [NS73831]
- Defeat GBM Program of the National Brain Tumor Society
- Ben and Catherine Ivy Foundation
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073831] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The cancer genome provides the blueprint for identifying oncogenic mutations driving tumor growth and these mutant proteins and pathways are the targets for precision cancer therapies. However, many oncogenes are capable of reprogramming the landscape of active portion of the genome, commonly known as the epigenome. This creates fluidity, and thereby heterogeneity, that demands consideration of this additional layer of complexity for effective therapeutic design and application. Molecular dissection of the epigenome may identify oncogene-induced, actionable vulnerabilities, broadening the spectrum of precision oncology treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available